Search

Your search keyword '"Filippatos, Gerasimos"' showing total 3,736 results

Search Constraints

Start Over You searched for: Author "Filippatos, Gerasimos" Remove constraint Author: "Filippatos, Gerasimos"
3,736 results on '"Filippatos, Gerasimos"'

Search Results

51. Percutaneous repair of moderate‐to‐severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE‐HF2 trial and comparison to COAPT and MITRA‐FR trials

53. Differences in presentation, diagnosis and management of heart failure in women. A scientific statement of the Heart Failure Association of the ESC

54. Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial

56. Dietary sodium and fluid intake in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC

58. Body mass index and cardiorenal outcomes in the EMPEROR‐Preserved trial: Principal findings and meta‐analysis with the DELIVER trial

59. Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR‐Pooled analysis

60. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial

62. Functional and Symptomatic Clinical Trial Endpoints: The HFC-ARC Scientific Expert Panel

64. Heart failure with normal LVEF in BIOSTAT-CHF

65. Medication dosing for heart failure with reduced ejection fraction — opportunities and challenges

67. Endothelial glycocalyx integrity in oncological patients

70. Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis

71. Decongestion, kidney injury and prognosis in patients with acute heart failure

72. A systematic review of miRNAs as biomarkers for chemotherapy-induced cardiotoxicity in breast cancer patients reveals potentially clinically informative panels as well as key challenges in miRNA research

74. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

75. Management of cardiac sarcoidosis: A clinical consensus statement of the Heart Failure Association, the European Association of Cardiovascular Imaging, the ESC Working Group on Myocardial & Pericardial Diseases, and the European Heart Rhythm Association of the ESC

76. Epidemiology and risk factors for hyperkalaemia in heart failure.

77. Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients hospitalized for acute heart failure: Data from STRONG‐HF.

79. Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial

80. Similar clinical benefits from below‐target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial

82. Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life: Insights From the STRONG-HF Trial

83. Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY population

84. Blood pressure and intensive treatment up‐titration after acute heart failure hospitalization: Insights from the STRONG‐HF trial

87. Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in EMPEROR‐Preserved

88. The effect of sodium–glucose cotransporter 2 inhibitors on left cardiac remodelling in heart failure with reduced ejection fraction: Systematic review and meta‐analysis

89. Epidemiology, pathophysiology, diagnosis and management of chronic right‐sided heart failure and tricuspid regurgitation. A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC

90. Variation Of Prespecified Subgroups In Large-Scale HF Outcome Trials

91. Safety Indicators In Patients Receiving High-intensity Care After Acute Heart Failure Admission: The STRONG-HF Trial

92. Autonomic Regulation Therapy To Improve Symptoms And Clinical Outcomes In Patients With Heart Failure And Reduced Ejection Fraction (ANTHEM-HFrEF) Pivotal Study Results

96. Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy

97. Serum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: Analysis of the ESC-EORP Heart Failure Long-Term (HF LT) Registry

100. Relation of Decongestion and Time to Diuretics to Biomarker Changes and Outcomes in Acute Heart Failure

Catalog

Books, media, physical & digital resources